Researchers combined IW-3718 with a proton pump inhibitor. The combination therapy significantly reduced heartburn severity in uncontrolled GERD patients.
Here’s what you should know:
1. Researchers analyzed data from 282 patients. The patients took a twice-daily oral dose of the therapy.
2. More than half of the patients achieved a “clinically meaningful reduction” in heartburn severity.
3. The therapy was well tolerated.
4. Ironwood will meet with the FDA to discuss the trial before advancing to phase III development in the latter half of 2018.
More articles on gastroenterology:
GI center to know: Eugene Gastroenterology Consultants
CMS proposes 2018 endoscopy anesthesia updates: 5 key highlights from CRH Anesthesia
GI leader to know: Dr. Alexandria Phan of Cancer Treatment Centers of America
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
